The biotherapeutics virus removal filters market is likely to get a boost because of increasingly relying on biomolecules and therapeutic agents in the biopharmaceutical and biotechnology industries. Furthermore, economically, the market will give an 8.5% CAGR upward movement during the forecast period from USD 526.2 million in 2025 to USD 1,189.9 million by 2035.
Such filters are a necessity for separating viral contaminations from biotherapeutic raw materials to ensure safety to the product and compliance with the standing rules. Improvements of focus go on manufacturing process keeping the viral outbreaks down and injection in the biologics increases and drives growth in the market.
Market Metrics
| Metric | Value |
|---|---|
| Market Size (2025E) | USD 526.2 Million |
| Market Value (2035F) | USD 1,189.9 Million |
| CAGR (2025 to 2035) | 8.5% |
North America is likely to dominate the biotherapeutics virus removal filters market due to the strong presence of biopharmaceutical corporations and main investments in the production of biologics and biosimilars. The region is beyond home to stringent regulatory bodies such as the FDA, which mandates high phases of safety and quality in biotherapeutic production.
Over and above that, the growing number of analysis and progress activities in biopharmaceuticals, coupled with the rising prevalence of viral diseases, is hoped-for to drive the demand for virus removal filters.
Notably, Europe has gained a portion of the global market due to very strong pharmaceutical and bioengineering sectors. Germany, Switzerland, and the UK are assumed to lead the production of biologics via virus removal filters.
The European Medicines Firm enforces stringent regulations on virus safety, thus increasing the number of filtration systems required in biotherapeutics manufacturing. There is a rising emphasis in the region on developing the safety of blood and plasma products, further aiding market development.
The biotherapeutics virus removal filters market is planned to grow in particular in the near future across the Asia-Pacific regions owing to the strengthening of pharmaceutical manufacturing capacities, growing investments in healthcare, and the developing number of agreement manufacturing organizations in countries like China, India, and Japan.
With the amplify in demand for biologics and biosimilars in the region, the forwarding in production technology accelerates the spreading of the virus removal filter market for biotherapeutics manufacturing.
High Initial Investment and Regulatory Complexity
One of the reasons for the slow entry of biotherapeutics into the market, despite their elevating popularity, is the high initial cost involved with installing such filtration systems. Some manufacturers may not become proficient to justify this warm of capital expenses, particularly in advancing markets. Another obstacle is the elaborate regulatory conditions that manufacturers need to comply with to guarantee the productivity of virus removal filters in conformity with quality and safety standards.
Increasing Adoption of Biologics and Advances in Filtration Technology
The demand for biologics has been on the rise owing to their effectiveness in chronic and rare disease therapy, thus providing a very lucrative opportunity for the virus removal filters market. Also, the increase in the development of biosimilars and gene therapies will provide further opportunities for market growth.
Some of the other factors that can drive the growth of this market are technological developments in filtration processes, by which efficient and cost-effective filters with high throughput have been developed. In addition, the continuing focus on improving manufacturing processes to curb contamination risks will provide a significant opportunity for the growth of virus removal filters.
The biotherapeutics virus removal filters market is likely to witness a boom between 2025 and 2035, on the back of demand pull for biopharmaceutical and biotherapeutic drugs as well as regulatory requirements with regard to virus safety for production of biologics.
The primary drivers of market growth are the increasing needs for virus clearance technologies for the production of therapeutic proteins, vaccines, and gene therapies. In parallel, with rapid growth in the number of biologics being clinically tested and a heightened appreciation for virus contamination risks in biomanufacturing, this demand for virus-removal filters is increasing.
The upgraded filters, membrane filters, chromatography systems, and other filter materials also enhance virus removal operations in terms of effectiveness and efficiency. Finally, virus clearance regulations promulgated by regulatory bodies such as FDA and EMA will push virus removal filters into the forefront of biopharmaceutical manufacture.
Market Shifts: 2020 to 2024 vs. 2025 to 2035
| Key Dimensions | 2020 to 2024 |
|---|---|
| Growth Drivers | Increasing number of biologics and vaccines, regulatory focus on virus clearance |
| Technology Trends | Filtration-based virus removal, chromatography techniques |
| Applications | Therapeutic proteins, vaccines, monoclonal antibodies, gene therapies |
| End-User Adoption | Biopharmaceutical companies, contract manufacturing organizations (CMOs) |
| Geographic Demand | North America, Europe |
| Regulatory Landscape | FDA and EMA virus removal guidelines for biologics |
| Innovation Focus | Membrane-based virus removal, virus filtration in vaccines |
| Supply Chain Dynamics | Well-established supply chain across North America and Europe |
| Key Dimensions | 2025 to 2035 |
|---|---|
| Growth Drivers | Surge in gene therapies, biosimilars, and global pandemic preparedness |
| Technology Trends | Advanced membrane filters, nanomaterial-based filters, automated filtration systems |
| Applications | Viral clearance in biologics production, vaccines, gene therapies, and cell and gene therapy manufacturing |
| End-User Adoption | Expanding biopharmaceutical and biotechnology companies, emerging markets in Asia |
| Geographic Demand | North America, Europe, Asia-Pacific, Latin America |
| Regulatory Landscape | Evolving global standards for gene therapies, biosimilars, and viral clearance in biologics manufacturing |
| Innovation Focus | Advanced filtration media, scalable filtration systems for large-scale biomanufacturing |
| Supply Chain Dynamics | Expanded global supply chains with manufacturers in emerging markets, including China and India |
The expansion of the biopharmaceutical industry and the increasing attention gently channeled toward biotherapeutic products' safety and efficacy have bloomed the biotherapeutics virus removal filters market in the USA.
These stringent regulatory guidelines established by FDA create a compelling demand for high-quality virus removal filters. The USA market is growing leaps and bounds due to technological advancements in filtration and the rising viral safety requirement for production of therapeutics.
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 8.5% |
The biotherapeutics virus removal filters marketin the UK is growing steadily with investments into biomanufacturing and filtration technology advancements. The country has been emphasizing on its efforts of improving the safety of biotherapeutic products particularly in the vaccine and blood plasma industries, thus improving the adoption of virus removal filters. To top that, a strong regulatory environment helps in market expansion within the country.
| Country | CAGR (2025 to 2035) |
|---|---|
| United Kingdom | 8.0% |
The biotherapeutics virus removal filters marketin the European Union, are effectively shaping due to the increasing demand for biologic drugs along with the direction of regulations on virus safety. The lenient legislation regarding virus removal processes in the EU ensures quite a high standard for biomanufacturing processes and pushes the market for virus removal filters. The growth factors for virus-removing filter markets also appear to be attributed to the growing vaccine industry and biopharmaceutical productions in Germany, France, and Switzerland.
| Country | CAGR (2025 to 2035) |
|---|---|
| European Union | 8.2% |
The Japanese biotherapeutics virus removal filters market is witnessing a steady growth trajectory, mainly spurred by the mature biopharmaceutical industry in Japan. The safety of biological therapeutics, be it plasma-derived therapies or vaccines, is duly scrutinized by the regulatory body; this is further lending momentum to the acceptance of virus removal filters.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 7.5% |
The rapidly expanding biopharmaceutical industry and investments in the R&D of biologic therapies drive growth in the biotherapeutics virus removal filters marketin South Korea. The growing emphasis of the country toward strengthening its regulatory standards concerning viral safety in drug production is increasing the demand for advanced filtration technologies to meet safety protocols.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 7.8% |
The ever-increasing biopharmaceutical demand has accelerated and is expected to boost an impressive momentum for biotherapeutics virus removal filters marketgrowth between 2025 and 2035. Doubts with regard to contamination of products are also rising in addition to the stringent regulatory provisions.
These filters remain crucial to safety and purity regarding any biotherapeutic product, i.e., monoclonal antibodies, enzymes, or plasma-derived therapies, thus becoming indispensable components in the control of viral contamination in biopharmaceutical manufacturing towards its expanse and diversification.
Size Exclusion Technology to Lead the Market
| Technology | Market Share |
|---|---|
| Size Exclusion Technology | 56.4% |
The Size Exclusion Technology segment is expected to propel the biotherapeutics virus removal filters market, accounting for 56.4% of the share in 2025. Virus removal is efficacious via size exclusion filters with respect to differences in the size of molecules particles, therefore they are able to provide high efficiency and selectivity towards viral particles while preserving the integrity of biotherapeutic products. They are generally beneficial for the production of monoclonal antibodies and the production of other biologics, supporting viral safety concepts.
New emerging biopharmaceutical industries will ensure the market demand for size exclusion filters is met as well as increasing application of monoclonal antibodies and vaccines. Furthermore, stringent regulations regarding virus contamination in biopharmaceutical production propel adoption of this technology.
Monoclonal Antibodies to Hold the Largest Share
| Application | Market Share |
|---|---|
| Monoclonal Antibodies | 41.8% |
In 2025, the Monoclonal Antibodies segment will be likely to capture the maximum market share at 41.8%. These therapeutic agents are effective in cancer, autoimmune disorders, infectious diseases, etc.; hence they have a rising demand, which will expand the scope of virus removal filtration in production.
The phenomenal growth of the monoclonal antibody market due to advancements in personalized medicine and immunotherapy also increases the demand for virus-removal filters. Increasing regulatory pressure for product safety and increasing complexity of biologics further expand this segment.
Steady growth is likely to be observed in the biotherapeutics virus removal filters market from 2025 to 2035 due to increasing requirements for biopharmaceutical products and regulatory pressure to ensure safety in therapeutic formulation. In addition, improved technologies for filtration drive demand.
Attention of safety on biologics because of an increased number of monoclonal antibodies, vaccines, and gene therapies had also contributed to the huge demand for virus removal filtration systems in the biopharmaceutical industry. There is also a high need for contamination-free and high purity biologics, with an increased number of viral outbreaks, which would perpetuate forward growth in the development and adoption of these filters.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Merck Group | 20-25% |
| Sartorius AG | 18-22% |
| Pall Corporation | 15-20% |
| Lonza Group | 10-15% |
| Asahi Kasei Corporation | 8-10% |
| Other Companies (combined) | 25-30% |
| Company Name | Key Offerings/Activities |
|---|---|
| Merck Group | In 2024, Merck launched a new range of virus removal filters specifically designed for large-scale biopharmaceutical production, offering enhanced virus retention and scalability. In 2025, Merck plans to expand its product line with advanced filters targeting viral contamination in cell culture media. |
| Sartorius AG | Sartorius introduced a new family of virus filters in 2024 that provide superior performance in removing enveloped viruses from therapeutic proteins. The company aims to enhance their portfolio with high-throughput filtration systems in 2025, focusing on efficiency and ease of use for biomanufacturers. |
| Pall Corporation | In 2024, Pall Corporation released a new, cost-effective, and disposable virus removal filter system aimed at small-scale biopharmaceutical manufacturing. The company plans to launch a multi-use, scalable filtration solution in 2025, aimed at large-scale gene therapy production. |
| Lonza Group | Lonza expanded its filtration portfolio in 2024 by introducing high-flow rate filters designed to meet the growing demand in viral safety for gene therapies. In 2025, Lonza plans to integrate AI and automation technologies into their virus removal systems for better process control. |
| Asahi Kasei Corporation | Asahi Kasei launched a next-generation virus removal filter in 2024 with a focus on improving membrane fouling resistance and increasing filter lifespan. In 2025, the company aims to enhance its offering with filters that target both small and large viruses in biologic drug formulations. |
Key Company Insights
Merck Group (20-25%)
Merck remains one of the dominant players in the biotherapeutics virus removal filters market, with a wide range of high-performance filtration products tailored for various stages of biopharmaceutical production. The company continues to lead the market with its innovative solutions that improve efficiency in viral safety testing and provide advanced contamination removal in large-scale operations.
Sartorius AG (18-22%)
Sartorius is highly regarded for its cutting-edge filtration solutions and the development of next-generation virus filters. The company’s commitment to research and development has resulted in products that are particularly favored for their virus retention capabilities and scalability, meeting the growing demand in biologics manufacturing.
Pall Corporation (15-20%)
Pall is a key player in the virus removal filters market, known for providing robust filtration solutions in the biopharmaceutical sector. The company is focused on cost-effective and scalable filtration technologies, which are crucial for both small and large-scale manufacturing, particularly for gene and cell therapies.
Lonza Group (10-15%)
Lonza’s extensive portfolio in biopharmaceutical manufacturing includes some of the most advanced virus filtration systems available. The company is particularly well known for its innovation in large-scale production solutions, which are becoming increasingly important as demand for gene therapies and biologics rises.
Asahi Kasei Corporation (8-10%)
Asahi Kasei has made significant strides in the biotherapeutics filtration market with its high-performance virus removal filters. The company’s focus on enhancing the longevity and durability of its products helps reduce overall production costs, making it an attractive option for pharmaceutical companies.
Other Key Players (25-30% Combined)
The overall market size for the biotherapeutics virus removal filters market was USD 526.2 million in 2025.
The market is expected to reach USD 1,189.9 million in 2035.
Demand for biotherapeutics virus removal filters will be driven by increasing demand for biologics, growing concerns about viral contamination in therapeutic proteins, advancements in filtration technologies.
The top 5 contributing countries are the United States, Germany, Japan, China, and the United Kingdom.
The protein a virus removal filters segment is expected to lead the market, owing to their effectiveness in removing viruses and contaminants from biologics.
Explore Life Science & Biotechnology Insights
Biotherapeutics Virus removal filters Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
